semaglutide: Clinical Trials

601 trials of semaglutide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

298 completed, 123 recruiting, 67 not yet recruiting, 52 active not recruiting. 162 Phase 3, 123 Phase 2, 110 Phase 1, 94 Phase 4, 44 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 3162Completed 92, Recruiting 28, Not yet recruiting 18, Active not recruiting 13, Unknown 5, Withdrawn 5, Terminated 1
Phase 2123Completed 48, Recruiting 31, Not yet recruiting 19, Active not recruiting 15, Unknown 5, Withdrawn 3, Terminated 2
Phase 1110Completed 79, Recruiting 17, Active not recruiting 6, Not yet recruiting 3, Terminated 2, Unknown 2, Withdrawn 1
Phase 494Recruiting 27, Completed 24, Not yet recruiting 12, Unknown 12, Active not recruiting 11, Enrolling by invitation 4, Terminated 2, Suspended 1, Withdrawn 1
Not applicable44Recruiting 17, Not yet recruiting 11, Completed 7, Unknown 6, Active not recruiting 2, Enrolling by invitation 1
Early Phase 15Recruiting 2, Enrolling by invitation 1, Not yet recruiting 1, Unknown 1

Follow semaglutide: new trials by email Literature Review of semaglutide trials Research Report on semaglutide

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)
Semaglutide (SEMA), Exercise module, Anti-inflammatory diet module - Severe Mental Illness, Depression / Major Depressive Disorder
Not applicableNot yet recruitingLudwig-Maximilians - University of Munich1402028-10-012026-05-14
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus
Semaglutide (Wegovy) weekly injection - Gestational Diabetes Mellitus (GDM), Metabolic Syndrome
Phase 2 / Phase 3Not yet recruitingUniversity of Massachusetts, Worcester2262027-09-012026-09-28
GLP-1 RA for Stage 1 Type 1 Diabetes
Semaglutide, Placebo - Stage 1 Diabetes Mellitus, Type 1
Phase 2Not yet recruitingChildren's Hospital Medical Center, Cincinnati152027-09-012026-02-24
Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer
Semaglutide (Wegovy®) - Breast Cancer (Early Breast Cancer), Obesity
Phase 2Not yet recruitingAarhus University Hospital322027-03-012026-11-02
Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity
Semaglutide - Pediatric Obesity, Obesity
Not yet recruitingErin Mauney122027-03-012026-11-02
Semaglutide for Low Back Pain
Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector) - Lower Back Pain, Obesity (BMI>30)
Phase 2Not yet recruitingWashington University School of Medicine2502027-02-012026-07-28
Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
Semaglutide - Diabetes Mellitus, Type 2
Not yet recruitingNovo Nordisk A/S6002027-01-312026-09-18
Semaglutide for the Treatment of Cannabis Use Disorder
semaglutide - Cannabis Use Disorder, Cue-reactivity
Phase 2Not yet recruitingMassachusetts General Hospital402027-01-102026-10-19
Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access
Semaglutide, Virtual Weight Management Coaching - Obesity, Chronic Kidney Disease
Phase 4Not yet recruitingKristin Clemens8802027-01-012026-10-05
SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.
Recombinant Zoster Vaccine (Shingrix; RZV), Semaglutide (Ozempic®), Placebo (saline injection) - Type 1 Diabetes Mellitus
Phase 2Not yet recruitingMinistry of Health, Saudi Arabia2402027-01-012026-05-29
Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer
Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program - Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
Phase 2Not yet recruitingThe Methodist Hospital Research Institute482027-01-012026-10-01
SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer
GLP-1 Receptor Agonist, Levonorgestrel IUD (Lng-IUD), Oral Progestins - Endometrial Cancer, Endometrial Cancer Stage I
Phase 4Not yet recruitingHospital Universitari de Bellvitge802027-01-012026-06-10
Validation & Intervention Testing for Aging, Longevity and Healthspan
Dapagliflozin 10Mg Oral Tablet, Semaglutide oral, Placebo - Aging, Functional Decline
Phase 2Not yet recruitingThe University of Texas Health Science Center at San Antonio12002027-01-012026-11-06
Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy Adults
Semaglutide (UI112), Semaglutide (UIC202611) - Bioequivalence, Pharmacokinetics
Phase 1Not yet recruitingKorea United Pharm. Inc.442027-01-012026-11-13
GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward
Semaglutide - Obesity, Childhood
Phase 4Not yet recruitingUniversity of Minnesota10202027-01-012026-11-17
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
Semaglutide 0.25 mg, Semaglutide 0.5 mg, Semaglutide 1.0 mg - Kidney Transplant Recipient
Phase 2 / Phase 3Not yet recruitingUniversity Health Network, Toronto372026-12-052026-11-05
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
Semaglutide + TAU, Placebo + TAU - Schizophrenia Disorder, Metabolic Syndrome
Phase 3Not yet recruitingAll India Institute of Medical Sciences, Bhubaneswar6002026-12-012026-08-18
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
Semaglutide (Rybelsus®), Placebo - Duchenne Muscular Dystrophy (DMD)
Phase 1 / Phase 2RecruitingVanderbilt University Medical Center302026-12-012026-11-12
A Research Study Investigating How a New Medicine NNC0721-5186 Works in Women Living With Overweight or Obesity
NNC0721-5186, Semaglutide, Placebo (NNC0721-5186) - Overweight, Obesity
Phase 1Not yet recruitingNovo Nordisk A/S1022026-11-132026-11-17
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
CagriSema, Semaglutide, Cagrilintide - Hypertension, Obesity
Phase 3Not yet recruitingNovo Nordisk A/S14082026-11-112026-11-05

Showing 20 of 601. Sign in to see all of them.

Conditions studied

Diabetes Mellitus, Type 2 (247)  ·  Obesity (214)  ·  Overweight (85)  ·  Diabetes Mellitus (81)  ·  Weight Loss (28)  ·  Non-alcoholic Fatty Liver Disease (21)  ·  Renal Insufficiency, Chronic (19)  ·  Diabetes Mellitus, Type 1 (14)  ·  Cardiovascular Diseases (11)  ·  Alcoholism (10)  ·  Metabolic Syndrome (10)  ·  Insulin Resistance (9)  ·  Prediabetic State (9)  ·  Inflammation (8)  ·  Pediatric Obesity (8)

Sponsors

Novo Nordisk A/S (238)  ·  Brigham and Women's Hospital (13)  ·  Eli Lilly and Company (7)  ·  University of Colorado, Denver (7)  ·  Mayo Clinic (6)  ·  University Medical Centre Ljubljana (5)  ·  Vanderbilt University Medical Center (5)  ·  Yale University (5)  ·  Boehringer Ingelheim (4)  ·  Chinese University of Hong Kong (4)  ·  AstraZeneca (3)  ·  Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (3)  ·  Merck Sharp & Dohme LLC (3)  ·  Pfizer (3)  ·  RenJi Hospital (3)

Countries

United States (234)  ·  Germany (103)  ·  Canada (91)  ·  China (75)  ·  United Kingdom (71)  ·  Denmark (67)  ·  Spain (62)  ·  Poland (61)  ·  Japan (56)  ·  Hungary (44)  ·  Italy (43)  ·  Mexico (39)  ·  Australia (38)  ·  Bulgaria (38)  ·  Argentina (37)

Top investigators

Shirley Wang, PhD, ScM (8)  ·  Aaron Kelly, PhD (2)

Results publications

PMID 31903692, PMID 32998732, PMID 32267058, PMID 39963952, PMID 30615985, PMID 31769496, PMID 39535683, PMID 35373893, PMID 29766634, PMID 29862621, PMID 29907893, PMID 30122305, PMID 31215727, PMID 33660198, PMID 33969456, PMID 29687620, PMID 29748996, PMID 32193837, PMID 32827435, PMID 35383100, PMID 36056351, PMID 37178435, PMID 38698650, PMID 39222642, PMID 39226070, PMID 27633186, PMID 33567185, PMID 34472698, PMID 35724304, PMID 36801984, PMID 39480988, PMID 40980163, PMID 28110911, PMID 28349387, PMID 28526920, PMID 29246950, PMID 29764222, PMID 33185364, PMID 33606902, PMID 33667417, PMID 33782832, PMID 34080123, PMID 35064550, PMID 35434913, PMID 35439567, PMID 35484580, PMID 35582947, PMID 36200477, PMID 36738088, PMID 37605636

NIH funding

2019 (20), 2023 (16), 2017 (13), 2018 (13), 2015 (12), 2025 (12), 2016 (5), 2014 (4), 2008 (2), 2009 (1), K12AR084234 (1), K23DK131345 (1), K23HL183845 (1), P01AA029545 (1), P30AG044271 (1)